CA 19-9 抗体
Quick Overview for CA 19-9 抗体 (ABIN6296794)
抗原
See all CA 19-9 抗体适用
宿主
克隆类型
标记
应用范围
-
-
原理
- Mouse anti-Human CA19-9 Antibody [Sodium Azide Free]
-
特异性
- Cytoplasmic
-
纯化方法
- Precipitin lines obtained after immuno-diffusion using mAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le) were used as the immunogen for the CA19-9 antibody.
-
免疫原
- Precipitin lines obtained after immuno-diffusion using mAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le) were used as the immunogen for the CA19-9 antibody.
-
-
-
-
应用备注
-
Flow Cytometry: 0.5-1 μg/million cells in 0.1ml
Immunofluorescence: 0.5-1 μg/mL
Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1)
Prediluted format: incubate for 30 min at RT (2) -
限制
- 仅限研究用
-
-
-
缓冲液
- In 1X PBS, BSA free, sodium azide free
-
储存液
- Azide free
-
储存条件
- 4 °C,-20 °C
-
储存方法
- 2-8°C. The azide-free format should be aliquoted and stored at -20°C or colder.
-
-
- CA 19-9 (Gastrointestinal Cancer Antigen CA19-9 (CA 19-9))
-
别名
- CA19-9
-
背景
-
Target Description: CA19-9, a carbohydrate epitope expressed on a high MW (>400 kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This mAb is excellent for staining of formalin-fixed, paraffin-embedded tissues.
抗原
-